Second Genome, which is applying genomics technology to the microbiome, is the latest in a growing string of gene technology companies to raise substantial funding.
US-based microbiome therapeutic developer Second Genome increased its series B round to $51m last week with an investment by corporate venturing unit SR One, illustrating the continued rise of genomic medicine in the startup space.
SR One, the corporate venture capital arm of pharmaceutical firm GlaxoSmithKline, added $8.4m to the $42.6m Second Genome raised in April this year, taking the company’s total funding to $67m.
The first tranche had come from Pfizer Venture Investments and Roche Venture Fund, the…
